- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Everest Medicines Ltd (1952)
Everest Medicines Ltd stock price live, this page displays HK 1952 stock exchange data. View the 1952 premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Everest Medicines Ltd real time stock price chart below.
What Is the Everest Medicines Ltd Stock Price Today?
The Everest Medicines Ltd stock price today is 68.85.
What Is the Stock Symbol for Everest Medicines Ltd?
The stock symbol for Everest Medicines Ltd is ""1952.""
What Stock Exchange Does Everest Medicines Ltd Trade On?
Everest Medicines Ltd is listed and trades on the Hong Kong stock exchange.
Is Everest Medicines Ltd a Good Stock to Buy?
Determining whether Everest Medicines Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1952 quote. (ISIN: KYG3224E1061)
What Is the Everest Medicines Ltd Stock Price Today?
The Everest Medicines Ltd stock price today is 68.85.
What Is the Stock Symbol for Everest Medicines Ltd?
The stock symbol for Everest Medicines Ltd is ""1952.""
What Stock Exchange Does Everest Medicines Ltd Trade On?
Everest Medicines Ltd is listed and trades on the Hong Kong stock exchange.
Is Everest Medicines Ltd a Good Stock to Buy?
Determining whether Everest Medicines Ltd—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the 1952 quote. (ISIN: KYG3224E1061)
Hong Kong
Currency in HKD
68.85
-1.55(-2.20%)
Delayed Data·
Fair Value
An estimate of a Everest Med's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.70
71.50
52 wk Range
18.18
77.55
1952 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
1952 is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Everest Med's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.7071.50
52 wk Range
18.1877.55
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Book Value / Share
1952 Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Everest Med's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceAnalysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Impressive gross profit margins
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Everest Medicines Ltd Company Profile
Everest Medicines Limited, a biopharmaceutical company, engages in the discovery, license-in, development, and commercialization of therapies and vaccines to address critical unmet medical needs in Greater China and other Asia Pacific markets. Its pipeline includes Nefecon, an oral formulation of budesonide for the treatment of immunoglobulin nephropathy (IgAN); Xerava, a fully synthetic fluorocycline intravenous antibiotic for the treatment of infections caused by susceptible gram-positive, gram-negative, and anaerobic pathogens; Taniborbactam, a beta-lactamase inhibitor (BLI) which is in phase 3 clinical trial for the treatment of patients with serious bacterial infections; and Etrasimod, an oral selective sphingosine 1-phosphate (S1P) receptor modulator which is in phase 3 clinical trial for to treat moderate-to-severe active ulcerative colitis. The company provides Zetomipzomib, an immunoproteasome inhibitor that is in phase 2b clinical trial, for a range of immune mediated disorders, including lupus nephritis; EVER001, a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor which is in the phase 1b clinical trial for the treatment of renal diseases; and mRNA platform therapeutic vaccines for cancer and autoimmune diseases. Further, it offers EVER206, a polymyxin derivative designed to treat f MDR gram negative bacterial infections reduce toxicity and nephrotoxicity which is in phase 1 of clinical trial. The company was incorporated in 2017 and is based in Shanghai, China.
Compare 1952 to Peers and Sector
Metrics to compare | 1952 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship1952PeersSector | |
|---|---|---|---|---|
P/E Ratio | −21.6x | −16.3x | −0.5x | |
PEG Ratio | 1.07 | 0.30 | 0.00 | |
Price/Book | 5.5x | 6.3x | 2.6x | |
Price / LTM Sales | 31.8x | 23.8x | 3.3x | |
Upside (Analyst Target) | −14.6% | 0.7% | 42.9% | |
Fair Value Upside | Unlock | −14.2% | 6.2% | Unlock |
Earnings
Latest Release
Mar 25, 2025
EPS / Forecast
-- / --
Revenue / Forecast
405.16M / --
FAQ
What Stock Exchange Does Everest Med Trade On?
Everest Med is listed and trades on the Hong Kong Stock Exchange stock exchange.
What Is the Stock Symbol for Everest Med?
The stock symbol for Everest Med is "1952."
What Is the Everest Med Market Cap?
As of today, Everest Med market cap is 2.44B.
What Is Everest Med's Earnings Per Share (TTM)?
The Everest Med EPS (TTM) is -3.25.
From a Technical Analysis Perspective, Is 1952 a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Everest Med Stock Split?
Everest Med has split 0 times.
How Many Employees Does Everest Med Have?
Everest Med has 665 employees.
What is the current trading status of Everest Med (1952)?
As of 12 Aug 2025, Everest Med (1952) is trading at a price of 68.85, with a previous close of 70.40. The stock has fluctuated within a day range of 68.70 to 71.50, while its 52-week range spans from 18.18 to 77.55.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.